IGM Biosciences Inc (OQ:IGMS)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 325 E Middlefield Rd
Tel: 1-212-6001902
Website: igmbio.com
IR: See website
Key People
Michael D. Loberg
Independent Chairman of the Board
Fred M. Schwarzer
President, Chief Executive Officer, Director
Misbah Tahir
Chief Financial Officer
Bruce Keyt
Chief Scientific Officer
Daniel Shinyu Chen
Chief Medical Officer
Business Overview
IGM Biosciences Inc is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients. It has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company's lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The Company is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR).
Financial Overview
For the six months ended 30 June 2020, IGM Biosciences Inc revenues was not reported. Net loss totaled to $36.5M. Results are not comparable due to year end change.
Employees: 91 as of Jun 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $2,090M as of Jun 30, 2020
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$63.79M as of Jun 30, 2020
Net annual income (TTM): -$61.45M as of Jun 30, 2020
Free cash flow (TTM): -$62.33M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 30,594,081 as of Jun 30, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.